Current Research: Pediatric Hematology-Oncology

AALL0232 -- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells.

This phase II trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia.

Eligibility

Patients may be eligible for this trial if:

• Patients must be eligible for and enrolled on AALL03B1.
• Patients must be 1 -30 years of age.
• Patients must have newly diagnosed B-precursor ALL.
• WBC Criteria
  • Age 1.000-9.999 years: WBC ≥ 50,000/μL
  • Age 10.000-30.999 years: Any WBC
  • Prior steroid therapy: Any WBC
  • Testicular disease: Any WBC
• Prior Therapy Restrictions
• Patients shall have had no prior cytotoxic chemotherapy with the exception of steroids and intrathecalcytarabine. Intrathecal chemotherapy with cytarabine is allowed prior to registration for patient convenience.
• Systemic chemotherapy must begin within 72 hours of this intrathecal therapy.
• Patients with Down syndrome are ineligible to enroll onto this study.

Trial Sponsor

• Cancer and Leukemia Group B (CALGB); National Cancer Institute (NCI); Eastern Cooperative Oncology Group (ECOG); Southwest Oncology Group (SWOG)

Project Begin Date

• May 2005

Tentative Project End Date

• Sept 2012

Back to Pediatric Hematology-Oncology Research

Revised March 31, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .